Industry-leading behavioral science tool SPUR™ is validated to predict adherence and will be offered through the Clinical ink technology platform
Newsroom
Industry-leading behavioral science tool SPUR™ is validated to predict adherence and will be offered through the Clinical ink technology platform
Clinical ink, a global life science technology company, announces the promotion of John Pappadakis from EVP, Global Business Development to Chief Commercial Officer and Megan Petrylak from EVP, Clinical Operations to Chief Operating Officer.
Clinical ink announces EDCXtra: An integrated web-based EDC, DDC and eCOA platform.
Clinical ink announced the appointment of Dr. Nicholas Alp as Chief Medical Officer will lead the creation of innovative solutions and commercial strategies for clinical trial technology based on his experience as an interventional cardiologist and clinical trialist.
Clinical ink announces an integrated suite of eClinical tools for cardiometabolic clinical trials.
Clinical ink is expanding its patient engagement suite with the inclusion of the SPUR™ behavioral diagnostic tool created by Observia.
Clinical ink is setting a new industry benchmark in advancing study build timelines. Harnessing the power of the latest eCOA technology, Clinical ink can now reduce study build timelines to as little as 10 days.
